Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Research

MD-Logic Artificial Pancreas System

A pilot study in adults with type 1 diabetes

  1. Eran Atlas, MSC1,
  2. Revital Nimri, MD1,
  3. Shahar Miller, BSC1,
  4. Eli A. Grunberg, BSC1 and
  5. Moshe Phillip, MD1,2
  1. 1The Jesse Z. and Sara Lea Shafer Institute for Endocrinology and Diabetes, The National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel;
  2. 2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  1. Corresponding author: Moshe Phillip, mosheph{at}post.tau.ac.il.
Diabetes Care 2010 May; 33(5): 1072-1076. https://doi.org/10.2337/dc09-1830
PreviousNext
  • Article
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Example of 24-h closed-loop session results conducted with subject 1. A: Glucose trace and the insulin treatment during the 24-h closed-loop trial with subject 1. The top graph shows the CGS readings (black line), reference YSI measurements (♦), and the meal times (▴). The bottom graph shows the insulin treatment delivered by the MDLAP (horizontal line = basal rate, vertical lines with ● = insulin boluses). B: Control variability grid analysis over a time period of 24 h for subject 1. C: Control variability grid analysis overnight (0000–0800 h) for subject 1. The nine zones of the CVGA are associated with different qualities of glycemic regulation: A, accurate control; lower B, benign deviations into hypoglycemia; B, benign control deviations; upper B, benign deviations into hyperglycemia; lower C, overcorrection of hypoglycemia; upper C, overcorrection of hyperglycemia; lower D, failure to deal with hypoglycemia; upper D, failure to deal with hyperglycemia; and E, erroneous control. In both figures, the circles represent the minimum/maximum glucose level taken from the relevant time period glucose readings during home care and the rectangles indicate the levels during the MDLAP-regulated closed-loop session. BG, blood glucose.

Tables

  • Figures
  • Table 1

    Subject characteristics

    Subject no.Age (years)Gender (female/male)BMI (kg/m2)A1C (%)Disease duration (years)Means ± SD of blood glucose level (mg/dl)*IU · kg−1 · day−1
    130Female22.95.919113 ± 540.72
    223Male21.278120 ± 350.59
    322Female26.56.28126 ± 440.63
    425Female22.45.48151 ± 660.72
    523Male20.07.114143 ± 480.72
    619Female19.57.45137 ± 491.04
    725Female19.87.110.5119 ± 431.08
    • ↵*As measured at home by CGS.

  • Table 2

    Average and range results from 8-h closed-loop sessions

    AverageRange
    Fasting sessions (n = 6, 9 sessions)
        Blood glucose at the beginning of the closed-loop session (mg/dl)237178–300
        Time to <180 mg/dl from system connection (h)2.130.5–4.43
        Time to stable blood glucose levels (h)4.42.3–6.75
        Blood glucose level at stabilization (mg/dl)11277–155
    Meal challenge sessions (n = 2, 3 sessions)
        Blood glucose at the beginning of the closed-loop session (mg/dl)9670–138
        Peak postprandial blood glucose level (mg/dl)234211–251
        Time to <180 mg/dl from meal onset (h)2.562.18–3
        Time to stable blood glucose levels (h)3.433–4.3
        Blood glucose level at stabilization (mg/dl)10270–134.5
PreviousNext
Back to top
Diabetes Care: 33 (5)

In this Issue

May 2010, 33(5)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MD-Logic Artificial Pancreas System
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MD-Logic Artificial Pancreas System
Eran Atlas, Revital Nimri, Shahar Miller, Eli A. Grunberg, Moshe Phillip
Diabetes Care May 2010, 33 (5) 1072-1076; DOI: 10.2337/dc09-1830

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

MD-Logic Artificial Pancreas System
Eran Atlas, Revital Nimri, Shahar Miller, Eli A. Grunberg, Moshe Phillip
Diabetes Care May 2010, 33 (5) 1072-1076; DOI: 10.2337/dc09-1830
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Suppl Material
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Research

  • Insulin Resistance Is Associated With Enhanced Brain Glucose Uptake During Euglycemic Hyperinsulinemia: A Large-Scale PET Cohort
  • Not Only Diabetes but Also Prediabetes Leads to Functional Decline and Disability in Older Adults
  • Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts
Show more Original Research

Emerging Treatments & Technologies

  • Estimating Visceral Fat Area by Multifrequency Bioelectrical Impedance
  • Efficacy of a Continuous GLP-1 Infusion Compared With a Structured Insulin Infusion Protocol to Reach Normoglycemia in Nonfasted Type 2 Diabetic Patients: A Clinical Pilot Trial
Show more Emerging Treatments & Technologies

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.